| (Values in U.S. Thousands) | Dec, 2011 | Dec, 2010 | Dec, 2009 | Dec, 2008 | Dec, 2007 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Kun Run Biotech Inc (KURU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Kun Run Biotechnology Ltd., through Hainan Zhonghe Pharmaceutical Co., Ltd. (`Zhonghe`), its China based indirect subsidiary, is engaged in the development, manufacture, marketing and sale of prescription polypeptide drugs. It uses solid phase peptide synthesis (SPPS) and advanced purifying technology to produce various therapeutic polypeptide drugs, of which is 'TP-5' most known for efficiently regulating humans' immune systems in order to defend and cure malignant diseases. The Company's principal products are polypeptide derivatives as well as chemical products. The Company maintains two state-of-art manufacturing plants and possesses one of the largest peptide synthesizing capacities across Asia. The Company's manufacturing and sales facilities are located in the City of Haikou, Hainan.
Fiscal Year End Date: 12/31